2014-08-15T13:28:34-05:00 2013-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2013-01-01 133870223 INTERNATIONAL AIDS VACCINE INITIATIVE INC INTE 2128471111 125 BROAD STREET NO 9TH FL NEW YORK NY 10004 LOUIS SCHWARTZ CFO 2128471111 2014-08-15 1 3019519090 2013 2015-11-30 17:44:51Z MARGARET MCGLYNN 125 BROAD STREET NO 9TH FL NEW YORK NY 10004 107811170 0 X WWW.IAVI.ORG X 1996 DE SEE PART III, LINE 1. 12 11 145 11 0 0 59232675 63996178 0 0 1853192 1340482 373183 1030216 61459050 66366876 24455364 19414399 0 0 24793547 20889808 0 0 1808812 19824500 18434960 69073411 58739167 -7614361 7627709 90186843 105112068 21657630 29307883 68529213 75804185 X INTERNATIONAL AIDS VACCINE INITIATIVE (IAVI) IS A GLOBAL INITIATIVE DEDICATED TO ENSURE THE DEVELOPMENT OF SAFE, EFFECTIVE, ACCESSIBLE, PREVENTIVE HIV VACCINES FOR USE THROUGHOUT THE WORLD. 0 0 44930224 18432414 RESEARCH AND DEVELOPMENT - IMPLEMENTING A FOCUSED AND INNOVATIVE RESEARCH AND DEVELOPMENT PROGRAM THAT NOT ONLY CATALYZES ACTION BY MULTIPLE STAKEHOLDERS BUT HELPS DRIVE THE FIELD. IAVIS R&D TEAM DESIGNS AND DEVELOPS HIV VACCINE CANDIDATES, AND CONDUCTS VACCINE TRIALS AND RELATED EPIDEMIOLOGICAL RESEARCH IN PARTNERSHIP WITH MORE THAN 50 ACADEMIC, BIOTECHNOLOGY, PHARMACEUTICAL AND GOVERNMENTAL INSTITUTIONS. IAVI R&D IS PRIORITIZING TWO PRIMARY APPROACHES TO PREVENTING HIV INFECTION: ENGAGING THE IMMUNE SYSTEM TO BLOCK INFECTION, AND TRAINING IT TO RECOGNIZE AND DESTROY CELLS THAT HAVE ALREADY BEEN INFECTED BY HIV. HIV VACCINE CANDIDATES ARE PUT THROUGH A RIGOROUS AND LENGTHY PROCESS OF CLINICAL EVALUATION TO ESTABLISH THEIR SAFETY AND EFFICACY. IAVI AND ITS PARTNERS SUBSCRIBE TO THE HIGHEST SCIENTIFIC AND ETHICAL STANDARDS FOR CONDUCTING TRIALS OF HIV VACCINE CANDIDATES, ONE THAT EMPHASIZES PROTECTING THE RIGHTS, WELL-BEING AND DIGNITY OF TRIAL VOLUNTEERS. IAVI AND ITS PARTNERS HAVE SO FAR DEVELOPED AND ADVANCED 14 VACCINE CANDIDATES INTO 27 EARLY-STAGE HUMAN TRIALS IN 11 COUNTRIES IN ASIA, AFRICA, EUROPE AND NORTH AMERICA. IAVI AND ITS PARTNERS HAVE ESTABLISHED A NETWORK OF SOPHISTICATED LABORATORIES AND CLINICAL RESEARCH CENTERS IN ASIA, AFRICA, EUROPE AND NORTH AMERICA. IAVI ALSO HAS LAUNCHED RESEARCH CONSORTIA TO ADDRESS THE MAJOR SCIENTIFIC PROBLEMS OF HIV VACCINE DEVELOPMENT AND BOOST THE NUMBER AND QUALITY OF NOVEL VACCINE CANDIDATES EVALUATED IN CLINICAL TRIALS. A MAJOR PORTION OF THE VACCINE RESEARCH THAT IAVI SUPPORTS IS CONDUCTED IN DEVELOPING COUNTRIES, WHERE 95% OF ALL NEW HIV INFECTIONS OCCUR. IAVI PRIORITIZES BUILDING TECHNICAL AND SCIENTIFIC CAPACITY IN THESE COUNTRIES. 5070501 981985 ADVOCACY, POLICY AND COMMUNICATIONS - ENSURING NATIONAL AND GLOBAL, POLITICAL, ECONOMIC AND SOCIETAL ENVIRONMENTS THAT DRIVE THE FASTEST POSSIBLE DEVELOPMENT OF AN ACCESSIBLE AIDS VACCINE AS OF A COMPREHENSIVE RESPONSE TO END THE PANDEMIC. STRENGTHEN LOCAL ADVOCACY CAPACITY AND RESEARCH PREPAREDNESS THROUGH WORKING WITH RESEARCHERS, COMMUNITIES AND STUDY PARTICIPANTS, ESPECIALLY WITH POPULATIONS MOST VULNERABLE TO HIV/AIDS AND IN COUNTRIES AND REGIONS MOST AFFECTED BY THE PANDEMIC WHERE THE NEED FOR HIV PREVENTION AND A VACCINE IS THE MOST IMPORTANT AND URGENT. 50000725 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 1 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 1 X 56 0 1 145 1 0 1 IN KE SF UK 0 0 0 0 0 0 0 0 X 12 11 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CT FL GA HI ID IL KS KY MA MI MN MS MO NH NJ NC ND OK OR PA RI SC TN UT VT VA WV WI X X PATRICK MOUTON 2128471137 125 BROAD STREET NO 9TH FL NEW YORK NY 10004 PAUL H KLINGENSTEIN CHAIR 2.00 X X 0 0 0 IAN GUST SECRETARY (UNTIL 12/6/13) 2.00 X X 0 0 0 ANNE M VANLENT TREASURER 2.00 X X 0 0 0 ALEX GODWIN COUTINHO BOARD MEMBER 1.00 X 0 0 0 JOHN D EVANS BOARD MEMBER (UNTIL 12/6/13) 1.00 X 0 0 0 REINHARD KURTH SEE SCH O BOARD MEMBER (UNTIL 6/27/13) 4.70 X 20400 0 0 GEOFFREY LAMB BOARD MEMBER 1.00 X 0 0 0 ADEL AF MAHMOUD BOARD MEMBER 1.00 X 0 0 0 PURNIMA MANE BOARD MEMBER 1.00 X 0 0 0 MAJIKE WIJNROKS BOARD MEMBER 1.00 X 0 0 0 HELEN REES BOARD MEMBER 1.00 X 0 0 0 MARY C TYDINGS BOARD MEMBER 1.00 X 0 0 0 ALICE ALBRIGHT BOARD MEMBER (UNTIL 3/15/13) 1.00 X 0 0 0 LORD FOWLER BOARD MEMBER 1.00 X 0 0 0 ROBIN WEISS SEE SCH O BOARD MEMBER 4.70 X 9568 0 0 MARGARET MCGLYNN PRESIDENT/CEO 35.00 X X 503191 0 28000 WAYNE KOFF CHIEF SCIENTIFIC OFFICER/SR. VP R&D 35.00 X 359331 0 47056 LOUIS SCHWARTZ CHIEF FINANCIAL OFFICER 35.00 X 244557 0 45358 LABEEB ABBOUD SENIOR VP, GENERAL COUNSEL 35.00 X 260752 0 43597 THOMAS HASSELL V.P. VACCINE DEVELOPMENT R&D 35.00 X 303227 0 44920 CHARLES R KING V.P. VACCINE DESIGN R&D 35.00 X 288907 0 28335 CHRISTOPHER PARKS EXEC DIR., VIRAL VACCINES 35.00 X 290205 0 39495 DEREK HODKEY EXEC DIR., R&D OPERATIONS 35.00 X 252700 0 42163 2532838 0 318924 59 0 1 0 EMMES CORPORATION 401 N WASHINGTON STREET ROCKVILLE MD 20850 CLINICAL RESEARCH STUDIES 887527 VEDDER PRICE PC 1633 BROADWAY 47TH FLOOR NEW YORK NY 10019 LEGAL 333790 AUSTRALIAN BIOLOGICS PTY LTD PO BOX 587 CRAIGIEBURN VICTORIA CA 3064 CLINICAL RESEARCH STUDIES 329936 C&G CONSULTING INCORP 186 SAND ROAD FAIRFIELD NJ 07004 TEMP. SERVICES 302123 KEMPER COST MANAGEMENT INC 3300 S LAKESIDE DR OKLAHOMA CITY OK 73179 EQUIPMENT MAINT. SERVICES 269709 11 52859698 11136480 63996178 1225832 1225832 41558944 41444294 114650 114650 114650 MISCELLANEOUS 900099 1030216 1030216 1030216 66366876 0 0 2370698 6752178 6752178 12662221 12662221 1257461 606336 534263 116862 15764006 11741646 3218922 803438 1290402 992996 228113 69293 1513650 1111091 318419 84140 1064289 775391 231170 57728 386486 372110 8426 5950 131920 11185 120735 180000 180000 66064 66064 1284751 379524 716685 188542 34271 11729 20712 1830 737922 557178 153582 27162 470232 292504 166717 11011 2054768 1631397 341610 81761 1056116 902637 124125 29354 815925 707325 102090 6510 1811971 1503295 284549 24127 414543 241948 152000 20595 RESEARCH&CLINICAL SVCS. 5208063 5098977 32415 76671 LAB SUPPLIES/EQUIPMENT 3035554 3034114 1440 EQUIPMENT RENTAL/MAINT. 560022 501487 47755 10780 SUBSCRIPTIONS & PUBS. 88662 78444 6768 3450 97690 35012 54510 8168 58739167 50000725 6929630 1808812 12278888 33470130 24106669 14692706 48640 12878129 12878129 4840816 778306 26884504 22515914 5609645 4368590 30176249 30837316 296447 8038251 90186843 105112068 4483537 4188315 2345859 3128312 12107136 19388689 731666 649071 1989432 1953496 21657630 29307883 X 56165250 57097809 12363963 18706376 68529213 75804185 90186843 105112068 X 7627709 -356556 225069 -221250 X 0 1 X 1 1 1 X 81029914 62108316 58170600 59232675 63996178 324537683 81029914 62108316 58170600 59232675 63996178 324537683 324537683 2162202 884611 1508589 1772736 1225832 7553970 400000 250000 918646 373183 1030216 2972045 335063698 0.96860 0.93160 X SCHEDULE A, PART II - OTHER INCOME: 2009: COLLABORATIVE AGREEMENT 400,000 2010: COLLABORATIVE AGREEMENT 250,000 2011: OTHER INCOME 7,054 COLLABORATIVE AGREEMENT 250,000 WRITE OFF DEFERRED RENT 661,592 TOTAL 918,646 2012: OTHER INCOME 123,183 COLLABORATIVE AGREEMENT 250,000 TOTAL 373,183 2013: OTHER INCOME 209,558 COLLABORATIVE AGREEMENT 250,000 WRITE OFF DEFERRED RENT 135,063 INNOVATION FUND RETURNED 353,000 LOAN FORGIVENESS 82,595 TOTAL 1,030,216 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 180000 180000 58559167 58739167 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 8552 26974 180000 180000 395526 250000 250000 250000 250000 1000000 1500000 0 0 0 5185810 4081428 1104382 19865490 17424979 2440511 1833204 1009507 823697 4368590 INTEREST RECEIVABLE 3422371 SECURITY DEPOSITS 223050 REFUNDABLE ADVANCE 351024 INTERCOMPANY RECEIVABLES 4041806 8038251 DEFERRED RENT PAYABLE 1565706 DEFERRED COMPENSATION PAYABLE 387790 1953496 X 66594113 -356556 646897 2116072 2406413 64187700 66064 2113112 2179176 66366876 62947736 646897 5740848 6387745 56559991 66064 2113112 2179176 58739167 PART X, LINE 2: FOR THE YEAR ENDED DECEMBER 31, 2013, MANAGEMENT OF IAVI HAS DOCUMENTED ITS CONSIDERATION OF FASB ASC 740-10, INCOME TAXES, THAT PROVIDES GUIDANCE FOR REPORTING UNCERTAINTY IN INCOME TAXES AND HAS DETERMINED THAT NO MATERIAL UNCERTAIN TAX POSITIONS QUALIFY FOR EITHER RECOGNITION OR DISCLOSURE IN THE CONSOLIDATED FINANCIAL STATEMENTS. THE REQUIRED TAX RETURNS FOR THE INTERNATIONAL AIDS VACCINE INITIATIVE, INC. (FEDERAL FORM 990, RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX), AS WELL AS THE REQUIRED CORPORATE TAX RETURNS FOR THE LIMITED LIABILITY COMPANIES, ARE SUBJECT TO EXAMINATION BY THE INTERNAL REVENUE SERVICE, GENERALLY FOR THREE YEARS AFTER THE RETURN HAS BEEN FILED. PART XI, LINE 2D - OTHER ADJUSTMENTS: REVENUE OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE 1,441,460. INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. REVENUE OF IAVI HOLDINGS, LLC, INCLUDED IN CONSOLIDATED 674,218. AUDIT REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. REVENUE OF IAVI LAB, LLC, INCLUDED IN CONSOLIDATED AUDIT 394. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. PART XI, LINE 4B - OTHER ADJUSTMENTS: INTER-COMPANY REVENUE, ELIMINATED IN CONSOLIDATED AUDIT 2,113,112. REPORT BUT INCLUDED IN IAVI, INC. FORM 990. PART XII, LINE 2D - OTHER ADJUSTMENTS: EXPENSES OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE 2,085,582. INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. EXPENSES OF IAVI HOLDINGS, LLC, INCLUDED IN CONSOLIDATED 675,041. AUDIT REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. EXPENSES OF IAVI HISTORIC HOLDINGS, LLC, INCLUDED IN 298. CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. EXPENSES OF IAVI LAB, LLC, INCLUDED IN CONSOLIDATED AUDIT 2,979,927. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. PART XII, LINE 4B - OTHER ADJUSTMENTS: INTER-COMPANY EXPENSES, ELIMINATED IN CONSOLIDATED AUDIT 2,113,112. REPORT BUT INCLUDED IN IAVI, INC. FORM 990. 1 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 638808 EUROPE 1 4 GRANTS TO RECIPIENTS LOCATED IN REGION 5762358 NORTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 38772 SOUTH ASIA 1 8 GRANTS TO RECIPIENTS LOCATED IN REGION 258503 SUB-SAHARAN AFRICA 2 16 GRANTS TO RECIPIENTS LOCATED IN REGION 5963780 SOUTH ASIA 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 950556 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 2355818 4 28 0 0 4 28 15968595 0 15968595 EAST ASIA AND THE PACIFIC RESEARCH & DEVELOPMENT 75371 WIRE TRANSFER EAST ASIA AND THE PACIFIC RESEARCH & DEVELOPMENT 563437 WIRE TRANSFER EUROPE RESEARCH & DEVELOPMENT 5342 WIRE TRANSFER EUROPE RESEARCH & DEVELOPMENT 7890 WIRE TRANSFER EUROPE RESEARCH & DEVELOPMENT 17433 WIRE TRANSFER EUROPE RESEARCH & DEVELOPMENT 25051 WIRE TRANSFER EUROPE RESEARCH & DEVELOPMENT 38730 WIRE TRANSFER EUROPE RESEARCH & DEVELOPMENT 134184 WIRE TRANSFER EUROPE RESEARCH & DEVELOPMENT 203258 WIRE TRANSFER EUROPE RESEARCH & DEVELOPMENT 3891576 WIRE TRANSFER NORTH AMERICA ADVOCACY, EDUCATION, POLICY & ACCESS 10277 WIRE TRANSFER NORTH AMERICA ADVOCACY, EDUCATION, POLICY & ACCESS 28495 WIRE TRANSFER SOUTH ASIA RESEARCH & DEVELOPMENT 13115 WIRE TRANSFER SOUTH ASIA RESEARCH & DEVELOPMENT 16724 WIRE TRANSFER SOUTH ASIA RESEARCH & DEVELOPMENT 38909 WIRE TRANSFER SOUTH ASIA RESEARCH & DEVELOPMENT 182887 WIRE TRANSFER SUB-SAHARAN AFRICA ADVOCACY, EDUCATION, POLICY & ACCESS 22758 WIRE TRANSFER SUB-SAHARAN AFRICA ADVOCACY, EDUCATION, POLICY & ACCESS 42000 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 322292 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 358597 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 724313 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 991390 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1019832 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1030150 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH & DEVELOPMENT 1365779 WIRE TRANSFER EUROPE RESEARCH & DEVELOPMENT 1438894 WIRE TRANSFER 11 15 1 0 0 0 0 0 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT WITH A COMPLIANCE OFFICER LOCATED IN EAST AFRICA THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT AND DONOR TERMS WHICH INCLUDES ROUTINE COMPLIANCE AND SUBSTANTIVE AUDITS, ROUTINE INTERNAL CONTROL QUESTIONNAIRES, AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES ON A REGULAR BASIS. 1 INDIGO CREATIVE SOLUTIONS LLC 2142 200TH ST CENTURIA WI 54824 161755259 N/A 6888 PROGRAM SUPPORT BLACK AIDS INSTITUTE 1833 W EIGHTH ST 200 LOS ANGELES CA 900574920 954742741 501(C)(3) 14393 PROGRAM SUPPORT UNIVERSITY OF ROCHESTER - INFECTIOUS DISEASES UNIT UNIV OF ROCHESTER MED CTR INFECTIOU DISEASES UNIT 601 ELMWOOD AVE BOX ROCHESTER NY 14642 160743209 501(C)(3) 20000 PROGRAM SUPPORT GLOBAL HIV VACCINE ENTERPRISE 125 BROAD STREET 9TH FLOOR NEW YORK NY 10004 203347314 N/A 20000 PROGRAM SUPPORT FUTURES INSTITUTE 41-A NEW LONDON TURNPIKE GLASTONBURY CT 06033 204816286 501(C)(3) 27870 PROGRAM SUPPORT PUBLIC HEALTH INSTITUTE (PHI) 555 12TH STREET 10TH FLOOR OAKLAND CA 94607 941646278 501(C)(3) 32391 PROGRAM SUPPORT VIRGINIA COMMONWEALTH UNIVERSITY DEPT OF PEDIATRICS OFFICE OF SPONSORED PROGRAMS RED TEAM 800 E LEIGH STREET SUITE 113 RICHMOND VA 232980568 546001758 501(C)(3) 45597 PROGRAM SUPPORT UNIVERSITY OF WASHINGTON 12455 COLLECTIONS DRIVE CHICAGO IL 60693 916001537 GOVERNMENT 49499 PROGRAM SUPPORT UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE 0934 LA JOLLA CA 92093 956006144 N/A 85890 PROGRAM SUPPORT THE WEIL MEDICAL COLLEGE CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 10021 136094042 501(C)(3) 85977 PROGRAM SUPPORT MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVE CAMBRIDGE MA 02139 042103594 N/A 108645 PROGRAM SUPPORT DANA FARBER CANCER INSTITITE DEPARTMENT OF CANCER IMMUNOLOGY AIDS 44 BINNEY STREET- BP431C BOSTON MA 02115 042263040 501(C)(3) 125000 PROGRAM SUPPORT LA JOLLA INSTITUTE FOR ALLERGY & IMMUNOLOGY 9420 ATHENA CIRCLE LA JOLLA CA 92037 330328688 501(C)(3) 243154 PROGRAM SUPPORT UNIVERSITY OF WISCONSIN-MADISON RESEARCH SPONSORED PROGRAM 21 N PARK STREET STE 6401 MADISON WI 537151218 366006492 501(C)(3) 363904 PROGRAM SUPPORT CHILDRENS HOSPITAL OF PHILADELPHIA 3535 MARKET STREET 12TH FLOOR PHILADELPHIA PA 19104 231352166 N/A 377001 PROGRAM SUPPORT NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES OFFICE OF TECHNOLOGY DEVELOPMENT ATTN DIRECTOR 6610 ROCKLEDGE DRIVE BETHESDA CA 208926606 530196960 N/A 400000 PROGRAM SUPPORT VETERANS MEDICAL RESEARCH FOUNDATION 3350 LA JOLLA VILLAGE DRIVE 151A SAN DIEGO CA 92161 330189397 501(C)(3) 468158 PROGRAM SUPPORT HARVARD MEDICAL SCHOOL PRES AND FELLOWS OF HARVARD 1350 MASSACHUSETTS AVENUE HOLYOKE CENTER CAMBRIDGE MA 02138 042103580 501(C)(3) 491227 PROGRAM SUPPORT THERACLONE SCIENCES INC 1124 COLUMBIA STREET SUITE 300 SEATTLE WA 98104 562442890 N/A 525000 PROGRAM SUPPORT AVAC GLOBAL ADVOCACY FOR HIV PREVENTION 9000 ROCKVILLE PIKE NEW YORK NY 10011 943240841 501(C)(3) 584473 PROGRAM SUPPORT THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA CA 92037 330435954 N/A 1909008 PROGRAM SUPPORT EMORY UNIVERSITY 1599 CLIFTON ROAD ATLANTA GA 30322 580566256 501(C)(3) 735134 PROGRAM SUPPORT 14 8 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT TERMS WHICH INCLUDES SUBSTANTIVE AUDITS, ROUTINE INTERNAL CONTROL QUESTIONNAIRES, AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES ON A REGULAR BASIS. X X X X 0 0 0 0 0 0 0 1 0 MARGARET MCGLYNN PRESIDENT/CEO 456775 0 41400 0 5016 0 28000 0 0 0 531191 0 0 0 WAYNE KOFF CHIEF SCIENTIFIC OFFICER/SR. VP R&D 329504 0 27637 0 2190 0 28000 0 19056 0 406387 0 0 0 LOUIS SCHWARTZ CHIEF FINANCIAL OFFICER 233341 0 9800 0 1416 0 26842 0 18516 0 289915 0 0 0 LABEEB ABBOUD SENIOR VP, GENERAL COUNSEL 221836 0 20640 0 18276 0 25967 0 17630 0 304349 0 0 0 THOMAS HASSELL V.P. VACCINE DEVELOPMENT R&D 265524 0 35927 0 1776 0 28000 0 16920 0 348147 0 0 0 CHARLES R KING V.P. VACCINE DESIGN R&D 270631 0 0 0 18276 0 28000 0 335 0 317242 0 0 0 CHRISTOPHER PARKS EXEC DIR., VIRAL VACCINES 239630 0 49159 0 1416 0 26657 0 12838 0 329700 0 0 0 DEREK HODKEY EXEC DIR., R&D OPERATIONS 231429 0 19855 0 1416 0 23107 0 19056 0 294863 0 0 0 PART I, LINE 7 BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). IN ADDITION TO THE ANNUAL BONUS PAYMENT, CHRISTOPHER PARKS AND THOMAS HASSELL ALSO PARTICIPATED IN IAVI'S RETENTION AND ONE-TIME MERITORIOUS BONUS PROGRAMS RESERVED FOR THE MOST DESERVING PERFORMERS. THESE PROGRAMS ARE HIGHLY SELECTIVE AND ARE AIMED AT HELPING ATTRACT AND RETAIN SUITABLY QUALIFIED KEY HIRES FROM THE FOR-PROFIT (INDUSTRY) MARKET AND REWARD MAJOR ACHIEVEMENTS THAT HAVE HAD SIGNIFICANT POSITIVE IMPACT ON IAVI'S RESOURCES OR SCIENTIFIC MILESTONES. FORM 990, PART VI, SECTION B, LINE 11 THE AUDIT AND FINANCE COMMITTEE REVIEWED AND APPROVED THE FORM 990 IN DETAIL WITH THE CONTROLLER AND CFO. IT WAS THEN SENT TO THE FULL BOARD BEFORE IT WAS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C IAVI HAS A CONFLICT OF INTEREST POLICY WHICH APPLIES TO ALL BOARD AND ADVISORY COMMITTEE MEMBERS, MANAGEMENT, STAFF AND CONSULTANTS. THE POLICY REQUIRES THAT ALL BOARD AND ADVISORY COMMITTEE MEMBERS, AS WELL AS THE SENIOR MANAGEMENT, FILE AN ANNUAL DISCLOSURE FORM, INDICATING WHETHER THERE ARE ANY POTENTIAL OR ACTUAL CONFLICTS AS DEFINED UNDER THE POLICY. IN ADDITION, ALL STAFF AND CONSULTANTS, AS WELL AS SENIOR MANAGEMENT AND BOARD AND ADVISORY COMMITTEE MEMBERS, ARE REQUIRED TO DISCLOSE ANY POTENTIAL OR ACTUAL CONFLICTS ON AN ONGOING BASIS. ANNUAL DISCLOSURE FORMS, AS WELL OTHER CONFLICT OF INTEREST DISCLOSURES THAT ARISE DURING THE YEAR, ARE FILED WITH AND REVIEWED BY THE GENERAL COUNSEL. IN ADDITION, THE AUDIT & FINANCE COMMITTEE REVIEWS CONFLICT OF INTEREST DISCLOSURES THAT INVOLVE A DIRECTOR, OFFICER, OR KEY EMPLOYEE. IN EACH CASE, THE REVIEW ENSURES THAT ANY CONFLICT OF INTEREST IS PROPERLY ADDRESSED, MITIGATED, AND/OR MANAGED. (BEGINNING IN 2014, CONFLICT OF INTEREST DISCLOSURES INVOLVING AN IAVI DIRECTOR, OFFICER, OR KEY EMPLOYEE, WILL BE SUMMARIZED AND PROVIDED TO THE CHAIR OF THE AUDIT & FINANCE COMMITTEE FOR REVIEW BY THE AUDIT & FINANCE COMMITTEE'S INDEPENDENT DIRECTORS). FORM 990, PART VI, SECTION B, LINE 15 ONCE EVERY TWO YEARS, THE COMPENSATION COMMITTEE OF THE BOARD, COMMISSIONS A COMPENSATION SURVEY OF THE CEO'S COMPENSATION PACKAGE. THE SURVEY COMPARES COMPENSATION PACKAGES OF CEO'S OF ORGANIZATIONS THAT ARE COMPARABLE TO IAVI. THE COMMITTEE REVIEWS THE RESULTS OF THE SURVEY AND RECOMMENDATIONS MADE, DISCUSSES THIS WITH THE BOARD BEFORE PROVIDING SPECIFIC GUIDANCE AND APPROVAL TO IAVI'S MANAGEMENT. THE COMPENSATION COMMITTEE DETERMINES THE APPROPRIATE PACKAGE FOR THE CEO AND THE BOARD CHAIR SHARES THIS INFORMATION WITH HUMAN RESOURCES FOR IMPLEMENTATION. IAVI ENGAGES AN EXTERNAL SPECIALIZED FIRM WITH EXPERTISE TO CONDUCT THE SURVEY AND PROVIDE RECOMMENDATION TO THE COMPENSATION COMMITTEE. THE LAST COMPENSATION REVIEW TOOK PLACE IN JANUARY 2013. FORM 990, PART VI, SECTION B, LINE 15B: IN CONJUNCTION WITH THE CEO'S COMPENSATIGN REVIEW, THE COMPENSATION COMMITTEE OF THE BOARD ALSO COMMISSIONS AN EXTERNAL COMPARATIVE COMPENSATION SURVEY OF ORGANIZATIONS SIMILAR TO IAVI, IN WHICH THE PACKAGES OF ALL OTHER OFFICERS AND KEY EMPLOYEES ARE BENCHMARKED AGAINST A MARKET TO DETERMINE APPROPRIATENESS OF PAY. THE COMMITTEE REVIEWS THE RESULTS AND RECOMMENDATIONS FROM THE SURVEY AND PROVIDES MANAGEMENT WITH SPECIFIC GUIDANCE IN ADDRESSING ANY DISPARITIES. USING BENCHMARK JOB CLASSIFICATIONS, ONCE EVERY 2 YEARS IAVI COMMISSIONS A COMPENSATION SURVEY, ACROSS ALL ITS OFFICES TO DETERMINE THE COMPETITIVENESS OF ITS COMPENSATION PROGRAMS AND TO ENABLE THE ORGANIZATION TO CONTINUE TO ATTRACT AND RETAIN THE RIGHT TALENT IN THESE VARIOUS MARKETS. IN MOST CASES THE LOCAL LABOR MARKET IS CONSIDERED AND FOR CERTAIN POSITIONS, REGIONAL MARKETS MUST BE TARGETED. THE RESULTS OF EACH SURVREY ARE REVIEWED WITH THE COMPENSATION COMMITTEE OF THE BOARD, WHICH GIVE MANAGEMENT OVERALL GUIDANCE ON COMPENSATION DIRECTION. BASED ON RECOMMENDATION AND GUIDANCE OF THE COMPENSATION CQMMITTEE, THE EXECUTIVE OFFICE AND HUMAN RESOURCES COMMUNICATE CHANGES TO ANY AFFECTED EMPLOYEES. ANY COMPENSATION CHANGES ARE DETERMINED BASED ON EXTERNAL COMPETIVENESS RELATIVE INTERNAL VALUE, INDIVIDUAL PERFORMANCE, TEAM DYNAMIC, AND IAVI'S ABILITY TO PAY. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE ON ITS WEBSITE. FORM 990, PART XI, LINE 9: FOREIGN EXCHANGE LOSS -249,029. FOREIGN EXCHANGE TRANSLATION ADJUSTMENT 27,779. FORM 990, PART VII, SECTION A: BOARD MEMBERS REINHARD KURTH AND ROBIN WEISS WERE PAID FOR CONSULTING SERVICES FOR CHAIRING SCIENTIFIC ADVISORY COMMITTEE. THESE FEES WERE NOT COMPENSATION FOR THEIR ROLE ON THE BOARD OF DIRECTORS. IAVI STICHTING HEREGRANCHT 208 1016 BS AMSTERDAM NL RESEARCH SUPPORT NL N/A N/A IAVI INC 1 IAVI HOLDING LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 262032322 HOLDING COMPANY DE IAVI INC C 674218 16246229 1.00000 1 IAVI HISTORIC HOLDING LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 263632621 HOLDING COMPANY DE IAVI INC C 1.00000 1 IAVI LAB LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 262031769 LAB RESEARCH DE IAVI HISTORIC HOLDING LLC C 394 11392539 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 IAVI HOLDING LLC A 674218 ACTUAL IAVI STICHTING B 1438894 ACTUAL IAVI HOLDING LLC D 12848129 ACTUAL